INTROPUCTION
Porphyrlas are diseases caused by disruptions In porphyrln-heme biosynthesis. They may be hereditary or chemically Induced and they may affect either the liver or the red cell (for a review, see ref. 
MATERIALS AND METHODS Porphyrogenlc drug Injection
Male and female C3H mice were Injected Intraperltoneally with 0.1 ml to 0.25 ml of allylIsopropylacetamlde (AIA) (a gift from Hoffman-La Roche, Nutley, N.J.) or dlcarbethyoxy-1,4-dlhydrocolIIdlne (DOC) (Aldrlch Chemical Co.), 130 mg each/Kg body weight. AIA was dissolved In 0.9J NaCI (w/v) and DOC was recrystalIzed twice from ethanol and dissolved In commercial olive oil. Mice Injected with either saline, oil, or both were used as controls. See the legend to Table 1 for additional details. Other heme Intermedlates/catabolIc products were purchased from Aldrlch Chemical Co.
RNA preparation
Livers and small Intestines were dissected and RNA was extracted by the guanldlne hydrcchlorlde procedure . RNA was quantltated by absorbance at 260 nm.
RNA alectrophores I s and blotting
Ten g of total cell RNA was glyoxalated and electrophoresed through 1.2% agarose gel . RNA from the gel was blotted onto a nylon mesh, Zetablnd (Cuno Inc.). The RNA was crosslInked to the Zetablnd by exposing It to 254 nm UV-llght for 3-5 mln. using a hand-held light source. DNA was nick translated to a specific activity of 2-4 x 10 cpm/yg and 2 x 10 cpm/ral of hybridization buffer was used. Blots were then hybridized and washed by the method of Church and Gilbert and exposed to X-ray film (Kodak, XAG (Fig. 1) . The final unhybrldlzed mRNA fraction (which should lack most or all of the mRNAs common to untreated and porphyric liver) was used to prepare P-labeled cDNA. This labeled cDNA was utilized to screen a mouse liver cDNA library that had been constructed using porphyric liver poly(A+) RNA and the vector, pUC 13 (J. Toole, unpublished) ( respectively (Table 1) . AIA Induces apo A-IV mRNA levels approximately 2 fold In females (Table 1) (Fig. 4) . Maximal levels of apo A-IV mRNA were attained by 10 hours post-Inject I on. mRNA levels decreased slightly between 10 and 24 hours, and again between 24 and 48 hours post-Inject Ion (Fig. 4) 
PISCUSSIQN
We have cloned several mRNAs that Increase In abundance In response to experimentally Induced porphyrla. One of these cDNA clones was Identified as opolIpoproteln A-IV by Its homo logy to rat apo A-IV and Its ability to hybridize mRNA that can be translated Into a protein of appropriate molecular weight (Fig. 2, data not shown) . Female mice show a somewhat greater Induction than males when porphyrla Is Induced with either of two drugs singly or In combination (Fig. 3, Table 1 ). When DDC, an Inhlbltor of the last enzyme In the heme pathway, ferrochelatase. Is used as the porphyrogenlc agent, an 8-28 fold Increase Is seen In apo A-IV mRNA levels (Fig. 3, Table 1 ). If AIA, an J_Q situ heme oxidizing agent, Is employed to Induce porphyrla, then a 2-3 fold Increase In apo A-IV mRNA Is observed (Fig. 3, Table 1 , data not shown). These differences probably reflect a true drug-specific bias, since other of our porphyrla-InductbIe cDNA clones have mRNAs that show the opposite drug preference (Buchberg and Klnnlburgh, In preparation). The kinetics of apo A-IV mRNA Induction are similar with each drug. Apo A-IV mRNA Increased by 4-6 hr. and reached maximal levels by 10 hr. post-Inject Ion (Fig. 4) . The apo A-IV mRNA levels then decreased slowly between 10 hr. and 48 hr. post-Inject I on to 50)1 of their maximal level (Fig. 4) . This relatively rapid Increase In apo A-IV mRNA suggests that porphyrla either 1.) stabilizes apo A-IV transcripts (In this case the t of the non-porphyrlc apo A-IV RNA must be 10 hr. or 1/2 the kinetics of Induction would appear slower), 2.) Increases the transcription of the apo A-IV gene, or 3.) Involves a combination of Increased RNA stability and Increased transcription. Experiments are currently underway to decide which of these mechanisms contributes to the rapid Increase In apo A-IV mRNA.
The physiologic basis of the large Increase In apo A-IV mRNA Is at present not known. He believe, however, that several characteristics of this response point toward a significant physiological role. 1.) The apo A-IV response to porphyrogenlc drugs Is limited to the target tissue; liver apo A-IV mRNA levels Increase but not Intestine apo A-IV mRNA (Figs. 3, 5) . 2.) The response Is rapid; liver apo A-IV mRNA reaches maximal levels between 6-10 hr. after Injection of the porphyrogenlc drug (Fig. 4) . 3.) Two drugs that Induce porphyrla In fundamentally different ways each produce an Increase In liver apo A-IV mRNA abundance (Fig. 3) . 4.) Other Inducers of hepatic gene expression, such as turpentine's Induction of the acute-phase response, do not Increase apo A-IV mRNA levels (data not shown). Taken together, these data suggest an Important physiological link between porphyrle and apo A-IV gene expression. Two major physiologic roles for apo A-IV mRNA Induction during porphyrla are suggested by our data: 1.) Apo A-IV gene expression Is Increased as an adaptive response to the prophyrla, e.g., apo A-IV acts as a detoxlfleant, or 2.) A rapid Imbalance of hepatic llpld netabollsm occurs during porphyrla. The subsequent Induction of apo A-IV would be, therefore, a response to Its function In llpld metabollsn. Further experimentation will be needed to define apo A-IV's role In porphyrla.
